(Q43140566)

English

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

scientific article published on 5 March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

author name string

Yumei Ye

1

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Kyle T Keyes

2

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Congfang Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Jose R Perez-Polo

4

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Yu Lin

5

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Yochai Birnbaum

6

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

publication date

5 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

American Journal of Physiology Heart and Circulatory Physiology

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

298

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

H1454-65

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Shear stress stimulates phosphorylation of eNOS at Ser(635) by a protein kinase A-dependent mechanism

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

The biology of incretin hormones

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFkappaB.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Survival kinases in ischemic preconditioning and postconditioning.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Mediating delta-opioid-initiated heart protection via the beta2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

CREB activation and ischaemic preconditioning

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Protein kinase D links Gq-coupled receptors to cAMP response element-binding protein (CREB)-Ser133 phosphorylation in the heart

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Differential activation of CREB by Ca2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00867.2009

21 January 2018

Identifiers

10.1152/AJPHEART.00867.2009

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43140566&oldid=1598642602"